FrancophonIA/ELRC3.0 huggingface dataset:
English: The injectable formulations can also be used for the treatment and prevention of endocarditis.
Slovenian: Formulacije za injiciranje se lahko uporabljajo tudi za zdravljenje in preprečevanje endokarditisa.
English: In some countries it is available under the trade names Amoxicilline Biogaran and Clamoxyl.
Slovenian: V nekaterih državah je na voljo pod tržnima imenoma Amoxicilline Biogaran in Clamoxyl.
English: • Bacteraemia (bacteria detected in the blood) that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Slovenian: • bakteriemije (bakterij v krvi), ki je povezana ali domnevno povezana z katerimi koli zgoraj navedenimi okužbami.
English: Questions and answers on Amoxil and associated names (amoxicillin)
Slovenian: Vprašanja in odgovori o zdravilu Amoxil in povezanih imenih (amoksicilin)
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there was a need to harmonise the prescribing information for Amoxil in the European Union (EU).
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je potrebna uskladitev informacij o predpisovanju zdravila Amoxil v Evropski uniji (EU).
English: The recommended dose of Amoxil varies depending on the infection it is used to treat, the way it is given, and the age and weight of the patient.
Slovenian: Priporočeni odmerek zdravila Amoxil je različen in je odvisen od okužbe, pri kateri se uporablja, načina dajanja in starosti ter telesne mase bolnika.
English: Having harmonised the indications, the CHMP also harmonised the recommendations on how to use Amoxil.
Slovenian: Po uskladitvi indikacij je odbor CHMP uskladil tudi priporočila o načinu uporabe zdravila Amoxil.
English: Additionally, Amoxil should no longer be used in several other indications (treatment of bronchitis, acute lung disease, urethritis (inflammation of the urethra, the tube that carries urine from the bladder out of the body), gonococcal infections, male genital infections, gonorrhoea (a sexually transmitted infection caused by bacteria called Neisseria gonorrhoeae), enteritis (inflammation of the small intestine) with bacteraemia and intra-abdominal infections such as peritonitis, cholecystitis and acute cholangitis, and serious infections caused by Haemophilus influenzae).
Slovenian: Poleg tega se zdravilo Amoxil ne sme več uporabljati pri več drugih indikacijah (zdravljenje bronhitisa, akutne pljučne bolezni, uretritisa (vnetja sečnice, cevke, ki prenaša urin iz sečnega mehurja ven iz telesa), gonokoknih okužb, okužb moških spolovil, gonoreje (spolno prenosljive okužbe, ki jo povzroča bakterija Neisseria gonorrhoeae), enteritisa (vnetja tankega črevesa) z bakteriemijo in okužbami v trebuhu, kot so peritonitis, holecistitis ter akutni holangitis, in resnih okužb, ki jih povzroča Haemophilus influenzae), saj se za zdravljenje teh bolezni antibiotiki ne uporabljajo več ali pa so drugi antibiotiki dokazano učinkovitejši od amoksicilina.
English: The CHMP agreed that the oral (to be taken by mouth) formulations of Amoxil (such as capsules, tablets and suspensions) can be used in adults and children for the treatment of the following bacterial infections:
Slovenian: Odbor CHMP se je strinjal, da se lahko peroralne formulacije (ki se zaužijejo prek ust) zdravila Amoxil (kot so kapsule, tablete in suspenzije) uporabljajo pri odraslih in otrocih za zdravljenje naslednjih bakterijskih okužb:
English: What is Amoxil?
Slovenian: Kaj je zdravilo Amoxil?
English: It contains the active substance amoxicillin which belongs to the ‘beta-lactam' family (the family that includes penicillins).
Slovenian: Vsebuje zdravilno učinkovino amoksicilin, ki spada v družino „betalaktamov“ (družino, ki vključuje peniciline).
English: Additionally, Amoxil must not be used in patients who have had severe allergic reactions to another type of beta-lactam antibiotic (e.g. a cephalosporin, carbapenem or monobactam).
Slovenian: Poleg tega se zdravilo Amoxil ne sme uporabljati pri bolnikih, ki so imeli hude alergijske reakcije na drugo vrsto betalaktama (npr. cefalosporin, karbapenem ali monobaktam).
English: The CHMP agreed that Amoxil must not be used in patients who are hypersensitive (allergic) to amoxicillin or any other ingredients of Amoxil, and to any of the penicillins.
Slovenian: Odbor CHMP se je strinjal, da se zdravilo Amoxil ne sme uporabljati pri bolnikih, ki so preobčutljivi (alergični) na amoksicilin ali katero koli drugo sestavino zdravila Amoxil in katere koli peniciline.
English: • Helicobacter pylori eradication;
Slovenian: • eradikacijo bakterije Helicobacter pylori,
English: • Community acquired pneumonia (infection of the lungs acquired outside the hospital);
Slovenian: • zunajbolnišnične pljučnice (okužbe pljuč, pridobljene zunaj bolnišnice),
English: Amoxil is also available as a solution for injection or infusion (drip) into a vein, and as a solution for injection into a muscle.
Slovenian: Zdravilo Amoxil je na voljo tudi v obliki raztopine za injiciranje ali infundiranje (kapalne infuzije) v veno in raztopine za injiciranje v mišico.
English: Oral Amoxil can also be used for the prevention of endocarditis (infection of the inner lining of the heart).
Slovenian: Peroralna oblika zdravila Amoxil se lahko uporablja tudi za preprečevanje endokarditisa (okužba notranje srčne ovojnice).
English: • Asymptomatic bacteriuria (bacteria detected in the urine) in pregnancy;
Slovenian: • asimptomatske bakteriurije (bakterij v urinu) med nosečnostjo,
English: • Bacterial meningitis (infection of the membranes around the brain and spine);
Slovenian: • bakterijskega meningitisa (vnetja membran, ki obkrožajo možgane in hrbtenico),
English: • Severe infections of the ear, nose and throat (such as mastoiditis, peritonsillar infections,
Slovenian: • hudih okužb ušesa, nosu in žrela (kot so mastoiditis, peritonzilarne okužbe, epiglotitis in sinusitis,
English: • Acute exacerbations of chronic bronchitis;
Slovenian: • akutnega poslabšanja kroničnega bronhitisa,
English: • Dental abscess with spreading cellulitis (inflammation of the deep skin tissue);
Slovenian: • zobnega abscesa s širjenjem celulitisa (vnetja globokega kožnega tkiva),
English: • Acute streptococcal tonsillitis and pharyngitis (infections of the tonsils and throat);
Slovenian: • akutnega streptokoknega tonzilitisa in faringitisa (okužbe mandljev in žrela),
English: • Severe dental abscess with spreading cellulitis;
Slovenian: • hudega zobnega abscesa s širjenjem celulitisa,
English: On 22 July 2013, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Amoxil in the EU.
Slovenian: Da bi uskladili dovoljenja za promet z zdravilom Amoxil v EU, je Evropska komisija 22. julija 2013 napotila zadevo na odbor CHMP.
English: • Acute bacterial sinusitis (infection of the sinuses);
Slovenian: • akutnega bakterijskega sinusitisa (okužbe sinusov),
English: • Acute exacerbations (flare-ups) of chronic bronchitis (inflammation of the airways in the lungs);
Slovenian: • akutnega poslabšanja (ponovnega izbruha) kroničnega bronhitisa (vnetja dihalnih poti v pljučih),
English: epiglottitis, and sinusitis when accompanied by severe systemic signs and symptoms);
Slovenian: če jih spremljajo hudi sistemski znaki ter simptomi),
English: • Acute cystitis;
Slovenian: • akutnega cistitisa,
English: Amoxil was identified as needing harmonisation by the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh).
Slovenian: Usklajevalna skupina za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v humani medicini (CMDh) je ugotovila, da je za zdravilo Amoxil potrebno usklajevanje.
English: • Acute pyelonephritis (kidney infection);
Slovenian: • akutnega pielonefritisa (ledvične okužbe),
English: • Acute otitis media (infection of the middle ear);
Slovenian: • akutnega vnetja srednjega ušesa (otitis media),
English: • Acute cystitis (infection of the bladder);
Slovenian: • akutnega cistitisa (okužbe sečnega mehurja),
English: • Community acquired pneumonia;
Slovenian: • zunajbolnišnične pljučnice,
English: • Acute pyelonephritis;
Slovenian: • akutnega pielonefritisa,
English: • Typhoid and paratyphoid fever;
Slovenian: • trebušnega tifusa in paratifusa,
English: These review procedures were started in November 2004.
Slovenian: Ti revizijski postopki so se začeli novembra 2004.
English: The competent authorities of the Member States will continue to keep the product under regular review.
Slovenian: Pristojne oblasti držav članic bodo zdravilo še naprej redno nadzorovale.
English: On the basis of the CHMP Opinion, the European Commission issued a Decision on 28 November
Slovenian: Na podlagi mnenja CHMP je Evropska komisija izdala odločbo dne 28. novembra 2005.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 31 REFERRAL
Slovenian: MNENJE ODBORA ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) V ZVEZI Z NAPOTITVIJO IZ ČLENA 31
English: Public7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail@emea.eu.int http://www.emea.eu.int
Slovenian: 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail@emea.eu.int http://www.emea.eu.int
English: * Notes: The information given in this document and Annexes reflect only the CHMP Opinion dated 23 June 2005.
Slovenian: * Opombe: Informacije, podane v tem dokumentu in Dodatkih odražajo samo mnenje CHMP z dne 23. junija 2005.
English: International Non-Proprietary Name (INN): LUMIRACOXIB
Slovenian: Mednarodno nelastniško ime (INN): LUMIRAKOKSIB
English: The Marketing Authorisation Holder of lumiracoxib provided written explanations by 10 January and 10 May 2005.
Slovenian: Imetnik dovoljenja za promet z lumirakoksibom je pisna pojasnila predložil do 10. januarja in 10. maja 2005.
English: Oral explanation was given by the Marketing Authorisation Holder on 18 January
Slovenian: Ustno obrazložitev je imetnik dovoljenja za promet podal 18. januarja 2005.
English: On 7 April 2005, the FDA (Food and Drug Administration) and the EMEA requested Pfizer to voluntarily withdraw Bextra (valdecoxib) from the market.
Slovenian: Dne 7. aprila 2005 sta FDA (Food and Drug Administration) in EMEA prosila podjetje Pfizer naj prostovoljno umakne zdravilo Bextra (valdekoksib) iz prometa.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended Summary of Product Characteristics in Annex III.
Slovenian: Seznam zadevnih imen proizvodov je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, skupaj s spremenjenim Povzetkom glavnih značilnosti zdravila v Dodatku III.
English: On 18 November 2004, the CHMP requested comprehensive cardiovascular safety information for these products.
Slovenian: Dne 18. novembra 2004 je CHMP za ta zdravila zahteval obsežnejše podatke o kardiovaskularni varnosti.
English: COX-2 inhibitors have been introduced in medical practice for treatment of patients with chronic inflammatory degenerative diseases such as rheumatoid arthritis and osteoarthritis.
Slovenian: Zaviralci COX-2 so bili v zdravniško prakso uvedeni za zdravljenje bolnikov s kroničnimi vnetnimi boleznimi kot so revmatoidni artritis in osteoartritis.
English: Upon consideration of all available data, the CHMP adopted an opinion for lumiracoxib on 23 June 2005 recommending the maintenance of the Marketing Authorisations for lumiracoxib containing medicinal products in the indications stated in the Summary of Product Characteristics as set out in Annex III.
Slovenian: Po upoštevanju vseh razpoložljivih podatkov je CHMP dne 23. junija 2005 sprejel mnenje za lumirakoksib, v katerem priporoča ohranitev dovoljenj za promet za zdravila, ki vsebujejo lumirakoksib, za indikacije, navedene v Povzetku glavnih značilnosti zdravila, kot je opredeljeno v Dodatku III.
English: In September 2004, the Marketing Authorisation Holder of rofecoxib informed the EMEA that new clinical trial (APPROVe) data for rofecoxib have revealed a risk of thrombotic cardiovascular events.
Slovenian: Septembra 2004 je imetnik dovoljenja za promet z rofekoksibom obvestil EMEA, da so podatki iz novega kliničnega preizkušanja (APPROVe) učinkovine rofekoksib pokazali tveganje za trombotične kardiovaskularne dogodke.
English: Therefore, on 20 April 2005 further to a request from the EC, the CHMP broadened the scope of the procedure under Article 31 of Directive 2001/83/EC, as amended and the review procedure under Article 18 of Council Regulation (EEC) No 2309/93, to include the assessment of serious skin reactions in the ongoing class review in addition to the cardiovascular safety aspects.
Slovenian: CHMP je zato na zahtevo ES dne 20. aprila 2005 postopek iz člena 31 Direktive 2001/83/ES, kot je bila spremenjena, ter revizijski postopek v skladu s členom 18 Uredbe Sveta (EGS) št. 2309/93, razširil tako, da se v revizijo razreda zdravil v teku poleg vidikov kardiovaskularne varnosti vključi tudi vrednotenje hudih kožnih reakcij.
English: The COX-2 inhibitors celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib and valdecoxib comprise a relatively new group of substances whose common pharmacological action is the selective inhibition of cyclooxygenase-2.
Slovenian: Zaviralci COX-2, celekoksib, etorikoksib, lumirakoksib, parekoksib, rofekoksib in valdekoksib sestavljajo relativno novo skupino snovi, katerih skupno farmakološko delovanje je selektivno zaviranje ciklooksigenaze-2.
English: These data resulted in the worldwide withdrawal of rofecoxib (Vioxx) from the market on 30 September 2004 by the Marketing Authorisation Holder and raised questions regarding the cardiovascular safety of other Cox-2 inhibitors.
Slovenian: Zaradi teh podatkov je imetnik dovoljenja za promet dne 30. septembra 2004 z vseh svetovnih tržišč umaknil rofekoksib (Vioxx), pojavila pa so se tudi vprašanja o kardiovaskularni varnosti drugih zaviralcev Cox-2.
English: Further to discussions at the CHMP October 2004 plenary meeting, the European Commission recommended that this public health issue on all aspects of cardiovascular safety including thrombotic events and cardio-renal events should be the subject of Community referrals under Article 31 of Directive 2001/83/EC, as amended regarding decentrally authorised products containing celecoxib, etoricoxib and lumiracoxib and subject to a review procedure under Article 18 of Council Regulation (EEC) No 2309/93, as amended regarding the centrally authorised products containing celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn).
Slovenian: Po razpravi Odbora za zdravila za uporabo v humani medicini (CHMP) na plenarni seji oktobra 2004 je Evropska komisija priporočila, da se za to vprašanje javnega zdravja o vseh vidikih kardiovaskularne varnosti, vključno s trombotičnimi dogodki in kardiorenalnimi dogodki, mora sprožiti napotitveni postopek Skupnosti v skladu s členom 31 dopolnjene Direktive 2001/83/ESv zvezi z zdravili, odobrenimi po decentraliziranem postopku, ki vsebujejo celekoksib, etorikoksib in lumirakoksib ter revizijski postopek v skladu s členom 18 Uredbe Sveta (EGS) št. 2309/93, kot je bila spremenjena, v zvezi z zdravili, odobrenimi po centraliziranem postopku, ki vsebujejo celekoksib (Onsenal), parekoksib (Dynastat/Rayzon) in valdekoksib (Bextra/Valdyn).
English: FOR ALL MEDICINAL PRODUCTS CONTAINING CELECOXIB, ETORICOXIB, LUMIRACOXIB, PARECOXIB, AND VALDECOXIB
Slovenian: ZA VSA ZDRAVILA, KI VSEBUJEJO CELEKOKSIB, ETORIKOKSIB, LUMIRAKOKSIB, PAREKOKSIB IN VALDEKOKSIB
English: Pfizer agreed to suspend sale and marketing of Bextra worldwide pending further discussions on the unfavorable risk versus benefit due to data on serious skin reactions.
Slovenian: Pfizer je soglašal, da zaradi podatkov o hudih kožnih reakcijah po vsem svetu ustavi prodajo in trženje zdravila Bextra do nadaljnje razprave o neugodnem razmerju med tveganji in koristmi.
English: EU/2/02/035/007 SevoFlo 100% Inhalation vapour, liquid
Slovenian: EU/2/02/035/007 SevoFlo 100% Para za inhaliranje,
English: 250 ml
Slovenian: 250 ml plastenka
English: Inhalation use Bottle (polyethylene naphthalate) with Quik-Fil (II) closure
Slovenian: Plastenka iz polietilennaft alata (PEN) z zaporko Quik-Fil (II)
English: Withdrawal period
Slovenian: tekočina
English: 1 bottle Not applicable.
Slovenian: Ni smiselno.
English: Further information on Giapreza can be found on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/giapreza
Slovenian: Nadaljnje informacije o zdravilu Giapreza so na voljo na spletni strani agencije: https://www.ema.europa.eu/en/medicines/human/EPAR/giapreza
English: What measures are being taken to ensure the safe and effective use of Giapreza?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Giapreza?
English: Giapreza (angiotensin II)
Slovenian: Giapreza (angiotenzin II)
English: The medicine should be prescribed by a physician experienced in the treatment of shock and is for use in a hospital setting.
Slovenian: Zdravilo sme predpisovati samo zdravnik z izkušnjami z zdravljenjem šoka in je namenjeno uporabi v bolnišnici.
English: After 3 hours, 70% of patients treated with Giapreza in addition to standard treatments had their average arterial blood pressure rise to above 75 mmHg (an acceptable level) or by at least 10 mmHg, compared with 23% of patients treated with placebo (a dummy treatment) and standard treatments.
Slovenian: Po treh urah je pri 70 % bolnikov, ki so prejemali zdravilo Giapreza poleg standardnega zdravljenja, povprečni arterijski krvni tlak narasel na več kot 75 mmHg (sprejemljiva raven) ali vsaj za 10 mmHg v primerjavi s 23 % bolnikov, ki so prejemali placebo (zdravilo brez učinkovine) in standardno zdravljenje.
English: The rise in blood pressure is expected to help prevent organ damage and reduce the number of deaths from this condition.
Slovenian: Zvišanje krvnega tlaka naj bi pripomoglo k preprečevanju poškodb organov in zmanjšanju števila smrti zaradi tega obolenja.
English: The European Medicines Agency therefore decided that Giapreza's benefits are greater than its risks and that it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Giapreza večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Giapreza is a medicine used in adults with dangerously low blood pressure (a condition known as shock).
Slovenian: Giapreza je zdravilo, ki se uporablja pri odraslih z nevarno nizkim krvnim tlakom (bolezenskim stanjem, znanim kot šok).
English: The company that markets Giapreza will carry out a study to further investigate the effectiveness and safety of Giapreza, including whether the medicine could prevent damage to organs and affect how long patients live.
Slovenian: Podjetje, ki trži zdravilo Giapreza, bo izvedlo študijo, v kateri bo dodatno proučilo učinkovitost in varnost tega zdravila, med drugim tudi, ali bi lahko preprečilo poškodbe organov in vplivalo na to, kako dolgo bolniki živijo.
English: It is given as a continuous infusion (‘drip') into a vein.
Slovenian: Daje se kot neprekinjena infuzija (kapalna infuzija) v veno.
English: The dose depends on the patient's weight and should be adjusted according to the patient's blood pressure.
Slovenian: Odmerek je odvisen od bolnikove telesne mase in ga je treba prilagoditi glede na njegov krvni tlak.
English: The active substance in Giapreza, angiotensin II, is the same as a hormone that the body produces.
Slovenian: Učinkovina v zdravilu Giareza, angiotenzin II, je isti kot hormon, ki ga telo proizvaja.
English: As for all medicines, data on the use of Giapreza are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Giapreza stalno spremljajo.
English: It is used when other treatments for raising blood pressure have not worked and contains the active substance angiotensin II.
Slovenian: Uporablja se, kadar druga zdravljenja za zvišanje krvnega tlaka niso delovala, in vsebuje učinkovino angiotenzin II.
English: Giapreza (angiotensin II) EMA/370784/2019
Slovenian: Giapreza (angiotenzin II) EMA/370784/2019
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Giapreza have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Giapreza upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: The side effects of Giapreza were similar to those of standard treatments and were considered manageable.
Slovenian: Neželeni učinki zdravila Giapreza so bili podobni učinkom pri standardnem zdravljenju in so se šteli za obvladljive.
English: Angiotensin II increases blood pressure by narrowing blood vessels and releasing another hormone (aldosterone) that increases the volume of blood circulating in the body.
Slovenian: Angiotenzin II povečuje krvni tlak z oženjem krvnih žil in sprostitvijo drugega hormona (aldosterona), ki povečuje količino krvi, ki kroži v telesu.
English: The main study showed that adding Giapreza to standard treatment was effective in increasing average blood pressure in patients in shock.
Slovenian: Glavna študija je pokazala, da je bilo dodajanje zdravila Giapreza k standardnemu zdravljenju učinkovito pri zviševanju povprečnega krvnega tlaka pri bolnikih v šoku.
English: An overview of Giapreza and why it is authorised in the EU
Slovenian: Pregled zdravila Giapreza in zakaj je odobreno v EU
English: Why is Giapreza authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Giapreza odobreno v EU?
English: Other information about Giapreza
Slovenian: Druge informacije o zdravilu Giapreza
English: Side effects reported with Giapreza are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Giapreza, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: For more information about using Giapreza, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Giapreza glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: A main study involving 344 patients in shock has shown that Giapreza is effective at raising blood pressure when other treatments have not worked.
Slovenian: V glavni študiji, v katero je bilo vključenih 344 bolnikov v šoku, je bilo ugotovljeno, da je zdravilo Giapreza učinkovito pri zviševanju krvnega tlaka, kadar druga zdravljenja niso delovala.
English: What benefits of Giapreza have been shown in studies?
Slovenian: Kakšne koristi zdravila Giapreza so se pokazale v študijah?
English: What is Giapreza and what is it used for?
Slovenian: Kaj je zdravilo Giapreza in za kaj se uporablja?
English: What are the risks associated with Giapreza?
Slovenian: Kakšna tveganja so povezana z zdravilom Giapreza?
English: The most common side effects with Giapreza (which may affect more than 1 in 10 people) are thromboembolic events (problems due to clots in blood vessels) and short-lived high blood pressure.
Slovenian: Najpogostejši neželeni učinki zdravila Giapreza (ki se lahko pojavijo pri več kot 1 bolniku od 10) trombembolični dogodki (težave zaradi strdkov v krvnih žilah) in prehodni visok krvni tlak.
English: For the full list of side effects and restrictions with Giapreza, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Giapreza glejte navodilo za uporabo.
English: How does Giapreza work?
Slovenian: Kako zdravilo Giapreza deluje?
English: How is Giapreza used?
Slovenian: Kako se zdravilo Giapreza uporablja?
English: These measures will help protect the environment.
Slovenian: Taki ukrepipomagajo varovati okolje.
English: - if you have or have ever had liver problems.
Slovenian: - če imate ali ste kdaj imeli težave z jetri.